{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:02:11Z","timestamp":1787169731235,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ijid.2021.08.055","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T02:30:53Z","timestamp":1629858653000},"page":"138-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1112-8010","authenticated-orcid":false,"given":"Liang","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoping","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peize","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hancheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijid.2021.08.055_bib0001","first-page":"13","article-title":"Evaluation of Sensititre\u00ae MYCOTB Panel for the Susceptibility Testing of Mycobacterium tuberculosis to First and Second Lines Anti-Tuberculosis Drugs","volume":"6","author":"Abdelrahman","year":"2016","journal-title":"Clin Med Diagn"},{"issue":"10150","key":"10.1016\/j.ijid.2021.08.055_bib0002","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"LANCET"},{"issue":"1","key":"10.1016\/j.ijid.2021.08.055_bib0003","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s12879-017-2746-5","article-title":"Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients","volume":"17","author":"Atif","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"10","key":"10.1016\/j.ijid.2021.08.055_bib0004","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.5588\/ijtld.18.0649","article-title":"What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?","volume":"23","author":"Bastard","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"10.1016\/j.ijid.2021.08.055_bib0005","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-world data: towards achieving the achievable in cancer care","volume":"16","author":"Booth","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijid.2021.08.055_bib0006","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01522-2019","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report","author":"Borisov","year":"2019","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.ijid.2021.08.055_bib0007","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.5588\/ijtld.20.0330","article-title":"Clinical perspectives on treatment of rifampicin-resistant\/multidrug-resistant TB","volume":"24","author":"Cox","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.ijid.2021.08.055_bib0008","article-title":"Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China","volume":"57","author":"Davies","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2021.08.055_bib0009","unstructured":"EndTB Consortium. endTB clinical and programmatic guide for patient management with new tb drugs. Version 4.0.2018."},{"issue":"1","key":"10.1016\/j.ijid.2021.08.055_bib0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/rccm.202001-0135OC","article-title":"Culture conversion in patients treated with bedaquiline and\/or delamanid. A prospective multicountry study","volume":"203","author":"Franke","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ijid.2021.08.055_bib0011","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/cpt.1633","article-title":"Nonrandomized real-world evidence to support regulatory decision making: Process for a randomized trial replication project","volume":"107","author":"Franklin","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ijid.2021.08.055_bib0012","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/cid\/ciu786","article-title":"Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort","volume":"60","author":"Guglielmetti","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ijid.2021.08.055_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205463","article-title":"High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa","volume":"13","author":"Hirasen","year":"2018","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ijid.2021.08.055_bib0014","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-144-9-200605020-00008","article-title":"Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome","volume":"144","author":"Holtz","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijid.2021.08.055_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105956","article-title":"nterim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and\/or delamanid in South Korea","volume":"167","author":"Kang","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.ijid.2021.08.055_bib0016","first-page":"ciaa1509","article-title":"Genotypic resistance of pyrazinamide but not MIC is associated with longer time to sputum culture conversion in patients with multidrug-resistant tuberculosis","author":"Kuhlin","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ijid.2021.08.055_bib0017","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S2213-2600(15)00036-3","article-title":"Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies","volume":"3","author":"Kurbatova","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"10202","key":"10.1016\/j.ijid.2021.08.055_bib0018","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(19)31882-3","article-title":"Management of drug-resistant tuberculosis","volume":"394","author":"Lange","year":"2019","journal-title":"LANCET"},{"issue":"2","key":"10.1016\/j.ijid.2021.08.055_bib0019","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01718-2020","article-title":"The potential impact of COVID-19-related disruption on tuberculosis burden","volume":"56","author":"McQuaid","year":"2020","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.ijid.2021.08.055_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200539","article-title":"Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial","volume":"13","author":"Meyvisch","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ijid.2021.08.055_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijmyco.2013.01.004","article-title":"Patients at high risk of tuberculosis recurrence","volume":"7","author":"Mirsaeidi","year":"2018","journal-title":"Int J Mycobacteriol"},{"issue":"5","key":"10.1016\/j.ijid.2021.08.055_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155968","article-title":"Programmatic management of drug-resistant tuberculosis: An updated research agenda","volume":"11","author":"Mitnick","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ijid.2021.08.055_bib0023","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00017-2018","article-title":"Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa","volume":"51","author":"Mohr","year":"2018","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ijid.2021.08.055_bib0024","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4103\/0970-2113.168113","article-title":"The incidence of recurrence of tuberculosis and its related factors in smear-positive pulmonary tuberculosis patients in Iran: A retrospective cohort study","volume":"32","author":"Moosazadeh","year":"2015","journal-title":"Lung India"},{"issue":"3","key":"10.1016\/j.ijid.2021.08.055_bib0025","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jid.2017.09.031","article-title":"The physicochemical basis of clofazimine-induced skin pigmentation","volume":"138","author":"Murashov","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"13","key":"10.1016\/j.ijid.2021.08.055_bib0026","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ijid.2021.08.055_bib0027","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"Prideaux","year":"2015","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ijid.2021.08.055_bib0028","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.5588\/ijtld.10.0679","article-title":"Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan","volume":"15","author":"Qazi","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2021.08.055_bib0029","first-page":"1","article-title":"Evolutionary journey of programmatic services and treatment outcomes among drug resistant tuberculosis (DR-TB) patients under National TB Elimination Programme in India (2005-2020)","author":"Sachdeva","year":"2021","journal-title":"Expert Rev Respir Med"},{"issue":"4","key":"10.1016\/j.ijid.2021.08.055_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002773","article-title":"Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization","volume":"16","author":"Strydom","year":"2019","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.ijid.2021.08.055_bib0031","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01770-2018","article-title":"Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study","volume":"53","author":"Sun","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ijid.2021.08.055_bib0032","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12879-021-05870-w","article-title":"Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial","volume":"21","author":"Weng","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2021.08.055_bib0033","series-title":"WHO treatment guidelines for drug-resistant tuberculosis. 2016 update","year":"2016"},{"key":"10.1016\/j.ijid.2021.08.055_bib0034","series-title":"WHO treatment guidelines for multidrug and rifampicin-resistant tuberculosis 2018 update Pre-final text","year":"2018"},{"key":"10.1016\/j.ijid.2021.08.055_bib0035","series-title":"Global tuberculosis report 2020","year":"2020"},{"key":"10.1016\/j.ijid.2021.08.055_bib0036","series-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment","year":"2020"},{"key":"10.1016\/j.ijid.2021.08.055_bib0037","series-title":"Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis","year":"2021"},{"issue":"1","key":"10.1016\/j.ijid.2021.08.055_bib0038","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221006883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971221006883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:01:30Z","timestamp":1761120090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971221006883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":38,"alternative-id":["S1201971221006883"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2021.08.055","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2021.08.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}